Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: heart failure therapeutics - Cytokinetics/Amgen

Drug Profile

Research programme: heart failure therapeutics - Cytokinetics/Amgen

Alternative Names: Cardiac sacromere activators; CK 0689705; CK 1122534; CK 1213296; CK 1316719; CK 689705

Latest Information Update: 09 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytokinetics
  • Developer Amgen; Cytokinetics
  • Class Cardiovascular therapies; Heart failure therapies; Small molecules
  • Mechanism of Action Cardiac myosin stimulants; Troponin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Heart failure

Most Recent Events

  • 16 Oct 2018 Cytokinetics plans a first-in-human phase I trial for AMG 594 in Heart failure by end of 2018
  • 26 Jul 2018 Cytokinetics plans to submit IND for Heart failure in 2018
  • 03 Jan 2018 Preclinical development is ongoing in Heart failure (9230396; Cytokinetics Pipeline, January 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top